Inactive Instrument

Acer Therapeutics Inc.

ACER

US00444P1084

Biotechnology & Medical Research

Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc

November 20, 2023 at 04:26 pm EST

On November 17, 2023, Harry S. Palmin, Chief Financial Officer, ceased to be an executive officer of Acer Therapeutics Inc.

Latest news about Acer Therapeutics Inc.

Acer Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Chris Schelling Ceases to Be Chief Executive Officer of Acer Therapeutics Inc	Nov. 20	CI
Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc	Nov. 20	CI
Acer Therapeutics Inc. Announces Executive Changes	Nov. 20	CI
Zevra Therapeutics Completes Acer Acquisition	Nov. 20	MT
Zevra Therapeutics, Inc. completed the acquisition of Acer Therapeutics Inc. from funds affiliated with TVM Capital Life Science and others.	Nov. 16	CI
Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index	Nov. 13	CI
Transcript : Acer Therapeutics Inc. - Shareholder/Analyst Call	Nov. 08
Acer Therapeutics Inc.(OTCPK:ACER) dropped from NASDAQ Composite Index	Nov. 08	CI
North American Morning Briefing : Inflation -2-	23-09-06	DJ
HC Wainwright Downgrades Acer Therapeutics to Neutral From Buy	23-09-05	MT
North American Morning Briefing : Chinese Data -2-	23-09-05	DJ
Top Midday Decliners	23-09-01	MT
Roth MKM Downgrades Acer Therapeutics to Neutral From Buy, Price Target is $1.50	23-09-01	MT
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	23-08-31	MT
Sector Update: Health Care	23-08-31	MT
Top Midday Gainers	23-08-31	MT
Zevra Therapeutics to Acquire Acer Therapeutics in Merger Deal	23-08-31	MT
Transcript : Acer Therapeutics Inc., Zevra Therapeutics, Inc. - M&A Call	23-08-31
Relief Therapeutics Sells License for Urea Cycle Disorder Drug to Acer Therapeutics	23-08-31	MT
Zevra Therapeutics, Inc. entered into definitive Agreement to acquire Acer Therapeutics Inc. for $91 million.	23-08-30	CI
Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics	23-08-30	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Acer Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-14	CI
Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 3000E Growth Index	23-06-23	CI

Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Companyâs product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Acer Therapeutics Inc.

Equities

ACER

US00444P1084

Biotechnology & Medical Research

Harry S. Palmin Ceases to Be Chief Financial Officer of Acer Therapeutics Inc

Latest news about Acer Therapeutics Inc.

Chart Acer Therapeutics Inc.

Company Profile

Sector Bio Therapeutic Drugs